Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen, Glaucus Proteomics, Purdue University, University of Florida


Nanogen Reports Decreased Revenues, Lays Off 10 Percent of Its Staff

San Diego-based Nanogen this week announced lower third-quarter revenues, strong growth in R&D spending, and a widened net loss.

The company also said that despite standing to pocket $25 million from a settled patent suit last month, it has decided to lay off 10 percent of its workforce in hopes of shaving $5 million off its burn rate next year. A spokesman said staff reductions totalling less than 20 people will continue over the next three to four weeks.


Glaucus Proteomics Closes Shop

Glaucus Proteomics, which had been developing technologies to produce protein and antibody microarrays. ceased its operations in October and laid off 19 employees, after a failed financing round. The Netherlands-based company had “the ink wet on a financing round of $19.5 million,” when the fourth investor, an institutional bank, pulled out at closing, said Ian Humphery Smith, Glaucus’ founder and COO, adding that “the company died quickly.”


Delving Into the Difference, Scientists Combine DNA, RNA Screening Methods

A team of scientists at Purdue University and the University of Florida used quantitative trait locus mapping and microarray analysis to identify candidate genes in Drosophila melanogaster.

In a paper published in the Oct. 22 issue of the Proceedings of the National Academy of Sciences, Lauren McIntyre, assistant professor of agronomy at Purdue University and Marta Wayne, assistant professor of zoology at the University of Florida, described a method to pinpoint target genes responsible for the variation that produces ovarioles — ovary chambers through which eggs pass in the female fruit fly.

The researchers used quantitative trait locus mapping (QTL), a screening method based on DNA difference, to identify regions in the genome that might influence ovariole numbers. Then, the scientists used microarray analysis to comb through the genes for RNA differences. They conclude that differences at the DNA and the RNA level together pointed to “a reasonable choice for a candidate gene,” McIntyre said.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.